COVID-19 Update – SERO is open. We continue to consult, evaluate and treat patients and their families at our existing locations.

Pembrolizumab for Melanoma

Posted on September 29, 2015 in News

New Drug Pembrolizumab Shows Durable Responses in Patients with Melanoma

A new drug has shown promise in treating patients with metastatic melanoma, giving hope to thousands with the disease.

“Long-term data from the KEYNOTE-001 study showed that the anti–programmed death 1 (PD-1) antibody pembrolizumab produces durable responses in metastatic melanoma patients. These results were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting held May 29 to June 2 in Chicago.

Pembrolizumab is approved as a second-line therapy for metastatic melanoma following treatment with either ipilimumab or, for patients with BRAF-mutated tumors, an oral BRAF inhibitor at a dose of 2 mg/kg every 3 weeks. Thus far, more than 2,000 melanoma patients have been evaluated in clinical trials with pembrolizumab.“

Read the full article.